# US 10,117,844 B2 · DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,117,844 B2 - Document ID: US10117844B2 - Status: Granted - Kind: B2 - Application number: 14/699,556 - Filed: 2015-04-29 - Published: 2015-11-12 - Granted: 2018-11-06 - Earliest claimed: 2012-01-06 - Assignees: Omthera Pharmaceuticals, Inc.; Chrysalis Pharma AG - Applicants: Omthera Pharmaceuticals, Inc.; Chrysalis Pharma AG - Inventors: Timothy J. Maines; Bernardus N. Machielse; Bharat M. Mehta; Gerald L. Wisler; Michael H. Davidson; Peter Ralph Wood - Web page: https://patentgrep.com/patent/US10117844B2 ## CPC - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)} - A61K 31/366: having six-membered rings, e.g. delta-lactones - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 3/06: Antihyperlipidemics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. ## Claims ### Claim 1 A method of treating hypertriglyceridemia, comprising orally administering to a patient having pre-treatment serum or plasma triglyceride levels of about 200 mg/dL to about 500 mg/dL a therapeutically effective amount of a pharmaceutical composition comprising: eicosapentaenoic acid (EPA), in an amount of 50% to 60% by weight; docosahexaenoic acid (DHA), in an amount of 17% to 23% by weight; and docosapentaenoic acid (C22:5 n-3) (DPA), in an amount of 1% to 8% by weight; wherein at least 90% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form; and wherein the composition is not administered at the same time as a statin. ### Claim 2 (depends on 1) The method of claim 1, wherein at least 95% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form. ### Claim 3 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 1.5%. ### Claim 4 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 2%. ### Claim 5 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 2.5%. ### Claim 6 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 3%. ### Claim 7 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 3.5%. ### Claim 8 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 4%. ### Claim 9 (depends on 1) The method of claim 1, wherein DPA is present in the composition in a weight percent amount of at least 4.5%. ### Claim 10 (depends on 1) The method of claim 1, wherein the composition comprises a unit dose of at least 500 mg of the composition. ### Claim 11 (depends on 1) The method of claim 1, wherein the composition comprises a unit dose of about 1 gram of the composition. ### Claim 12 (depends on 1) The method of claim 1, comprising orally administering a dose of 2-4 grams per day of the composition. ### Claim 13 (depends on 12) The method of claim 12, wherein the dose is 2 grams per day. ### Claim 14 (depends on 1) The method of claim 1, further comprising orally administering to the patient a therapeutically effective amount of rosuvastatin, wherein the composition is not administered at the same time as the rosuvastatin. ### Claim 15 (depends on 1) The method of claim 1, wherein the patient is concurrently on statin therapy. ### Claim 16 (depends on 15) The method of claim 15, wherein the statin is selected from pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, rosuvastatin, tenivastatin, and pitavastatin. ### Claim 17 (depends on 15) The method of claim 15, wherein the statin is rosuvastatin. ### Claim 18 (depends on 1) The method of claim 1, comprising administering the composition for a duration effective to reduce serum or plasma triglycerides by at least about 5% below pre-treatment levels. ### Claim 19 (depends on 1) The method of claim 1, comprising administering the composition for a duration effective to reduce serum or plasma triglycerides by at least about 10% below pre-treatment levels. ### Claim 20 (depends on 12) The method of claim 12, wherein the dose is 4 grams per day. ### Claim 21 A method of treating hypertriglyceridemia, comprising orally administering to a patient having pre-treatment serum or plasma triglyceride levels of about 200 mg/dL to about 500 mg/dL a therapeutically effective amount of a pharmaceutical composition and a therapeutically effective amount of a statin; wherein the pharmaceutical composition comprises: eicosapentaenoic acid (EPA), in an amount of 50% to 60% by weight; docosahexaenoic acid (DHA), in an amount of 17% to 23% by weight; and docosapentaenoic acid (C22:5 n-3) (DPA), in an amount of 1% to 8% by weight; wherein at least 90% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form; the statin is administered on a dosage schedule different from the pharmaceutical composition; and the method comprises administering a single statin. ### Claim 22 (depends on 21) The method of claim 21, wherein the statin is selected from pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, rosuvastatin, tenivastatin, and pitavastatin. ### Claim 23 (depends on 21) The method of claim 21, wherein the statin is rosuvastatin. ### Claim 24 (depends on 21) The method of claim 21, wherein the composition is not administered at the same time as a statin. ### Claim 25 (depends on 21) The method of claim 21, wherein at least 95% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form. ### Claim 26 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 1.5%. ### Claim 27 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 2%. ### Claim 28 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 2.5%. ### Claim 29 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 3%. ### Claim 30 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 3.5%. ### Claim 31 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 4%. ### Claim 32 (depends on 21) The method of claim 21, wherein DPA is present in the composition in a weight percent amount of at least 4.5%. ### Claim 33 (depends on 21) The method of claim 21, wherein the composition comprises a unit dose of at least 500 mg of the composition. ### Claim 34 (depends on 21) The method of claim 21, wherein the composition comprises a unit dose of about 1 gram of the composition. ### Claim 35 (depends on 21) The method of claim 21, comprising orally administering a dose of 2-4 grams per day of the composition. ### Claim 36 (depends on 35) The method of claim 35, wherein the dose is 2 grams per day. ### Claim 37 (depends on 35) The method of claim 35, wherein the dose is 4 grams per day. ### Claim 38 (depends on 21) The method of claim 21, comprising administering the composition for a duration effective to reduce serum or plasma triglycerides by at least about 5% below pre-treatment levels. ### Claim 39 (depends on 21) The method of claim 21, comprising administering the composition for a duration effective to reduce serum or plasma triglycerides by at least about 10% below pre-treatment levels. ### Claim 40 A method of treating hypertriglyceridemia, comprising orally administering to a patient having pre-treatment serum or plasma triglyceride levels of about 200 mg/dL to about 500 mg/dL a therapeutically effective amount of a pharmaceutical composition comprising polyunsaturated fatty acids as the sole active pharmaceutical ingredient; wherein at least 90% by weight of the polyunsaturated fatty acid in the composition is present in the free acid form; and the polyunsaturated fatty acids comprise: eicosapentaenoic acid (EPA), in an amount of 50% to 60% by weight of the composition; docosahexaenoic acid (DHA), in an amount of 17% to 23% by weight of the composition; and docosapentaenoic acid (C22:5 n-3) (DPA), in an amount of 1% to 8% by weight of the composition. ### Claim 41 (depends on 40) The method of claim 40, wherein the polyunsaturated fatty acids further comprise: heneicosapentaenoic acid (C21:5 n-3); arachidonic acid (C20:4 n-6) (AA); eicosatetraenoic acid (C20:4 n-3); moroctic acid (C18:4 n-3); docosapentaenoic acid (C22:5 n-6); and linoleic acid (C18:2 n-6). ### Claim 42 (depends on 40) The method of claim 40, wherein the patient is concurrently on statin therapy with a statin selected from pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, rosuvastatin, tenivastatin, and pitavastatin. ### Claim 43 (depends on 40) The method of claim 40, wherein the patient is concurrently on statin therapy with rosuvastatin.